Endo, INC

Mallinckrodt plc has completed its acquisition of Endo, Inc., which subsequently converted into Endo LP, a Delaware limited partnership, and delisted its common stock from the OTCQX Best Market.

Endo, Inc. announced the successful outcomes of its 2025 Annual Meeting of Shareholders, confirming the re-election of all directors, advisory approval of executive compensation, and a commitment to annual advisory votes on executive pay.

Shareholders of Mallinckrodt plc and Endo, Inc. have overwhelmingly approved the proposed stock and cash transaction, clearing a major hurdle for the creation of a global, diversified pharmaceuticals leader.

Endo, Inc. reports a 6% decrease in total revenues for the first quarter of 2025 but reaffirms its full-year financial guidance.

Mallinckrodt and Endo have announced a proposed business combination, with Mallinckrodt filing a registration statement with the SEC.

Endo Inc. has approved cash retention bonuses for its executive officers to incentivize them to remain with the company and facilitate the completion of its merger with Mallinckrodt plc.

Endo Inc.'s Q1 2025 results reflect the impact of fresh start accounting following its bankruptcy emergence, along with strategic moves including a planned merger with Mallinckrodt and the divestiture of its International Pharmaceuticals business.

Endo Inc. releases its third quarter 2024 financial results, marking its first reporting period as a reorganized entity following its emergence from Chapter 11 bankruptcy.

Endo Inc. released its second quarter 2024 financial results, marking its first reporting period as a reorganized entity after emerging from Chapter 11 bankruptcy.

Endo, Inc.'s 10-K filing details its financial performance post-reorganization, strategic initiatives, and risk factors for the year ended December 31, 2024.

Mallinckrodt and Endo are urging their respective shareholders to vote in favor of the proposed business combination at the upcoming special meetings on June 13, 2025.

Mallinckrodt and Endo report significant progress in their proposed merger, with the S-4 registration statement becoming effective, the HSR waiting period expiring, and shareholder votes scheduled for June 13, 2025.

Mallinckrodt reports significant progress in its planned merger with Endo, having cleared SEC and antitrust hurdles and scheduled shareholder meetings.

Mallinckrodt announces positive Q1 2025 results with top-line growth and increased Acthar sales, while progressing towards its merger with Endo expected in the second half of 2025.

Endo, Inc. announces its Q1 2025 financial results, highlighting revenue of $393 million and adjusted EBITDA of $99 million, while reaffirming its full-year financial guidance and progressing with its merger with Mallinckrodt.

Endo reaffirms its 2025 financial guidance, projecting revenues between $1,775 and $1,860 million and adjusted EBITDA between $620 and $650 million, while advancing its merger with Mallinckrodt.

Endo, Inc. has filed supplemental disclosures to its definitive proxy statement in response to shareholder complaints and demand letters challenging its proposed merger with Mallinckrodt plc, aiming to moot claims and avoid transaction delays.

Endo, Inc. has released its definitive proxy statement outlining proposals for its 2025 Annual Meeting, including director elections, executive compensation, and the appointment of its independent auditor, while highlighting strong 2024 financial and operational performance following its Chapter 11 reorganization.

Mallinckrodt is set to acquire Endo, pending shareholder and regulatory approvals, in a deal that will reshape both companies and potentially lead to a NYSE listing for the combined entity.

Endo, Inc. amends and restates its non-employee director compensation policy, outlining annual equity and cash retainers effective July 23, 2024, as the company prepares for a possible public listing.

Endo International completes its financial restructuring and emerges from Chapter 11 bankruptcy as Endo, Inc., a specialty pharmaceutical company with a stronger balance sheet and a focus on growth.

Marathon Asset Management and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% of Endo, Inc.'s common stock, indicating a passive investment.